At the end of this presentation, the participant will be able to:

• Define the rol of brachytherapy for cervical cancer 
• Analyze the results of alternatives to brachytherapy
• Discuss possible difficulties in light of new systemic attitudes (Interlace) 

At the end of this presentation, the participant will be able to:

• Enumerate the possible gains for this attitude 
• Analyze the step to acheive adaptation
• Explain the gain with this attitude

At the end of this presentation, the participant will be able to:

• Analyze the relationship between brachytherapy's dose and the immune system.
• Understand the immune changes after brachytherpy.
• Outline clinical trials evaluating immunogenicity of brachytherapy.

At the end of this presentation, the participant will be able to:

• Identified particularities which makes a case challenging
• Explain evaluation of patient for GYN brachytherapy
• Outline how to adress dosimetry of difficult GYN brachytherapy cases
• Discuss the difference between an MRI vs a Scan/MRI workflow

At the end of the talk, the participant will be able to :

• Explain AI in brachytherapy
• Discuss the potential of AI in brachytherapy
• Discribe steps of brachytherapy where AI could help the workflow

At the end of this presentation, the participant will be able to:

• Discuss possible unconscious bias in the database
• Discuss role of human judgment in AI
• Explain AI ethic issues

At the end of this presentation: the participant will be able to:

• Explain the key elementd of law 5
• Understand the act respecting health and social services information 
• Enumerate the grey areas that create legal uncertainty 
• Discuss the practical ways to facilitate AI research and AI  integration in the health sector

At the end of this talk, the participant will be able to:

• Define the rationale for using biophysical models in brachytherapy
• Discuss the general utility of the TG-267 report and the radiobiological features
• Understand the potential clinical impact of the diverse temporal dose delivery patterns used in different brachytheray modalities.

At the end of this talk, the participant will be able to:

• Describe motion sensor tracking systems 
• Clarify dose received to personnel in an emergency situation
• Understand the necessity of these systems

At the end of this talk, the partiticant will be able to:

• Understand brachytherapy tracking thecnology
• Discuss the benefit of tracking in brachytherapy 
• Explain potential clinical workflow using tracking technology

At the end of this talk, the participant will be able to: 

• Discuss the benefit of Y-90
• Explain the rationnate for using this technology
• Understand potential clinical worflow

At the en of this talk, the participant wille be able to:

• Understand possible radionuclides used for brachytherapy 
• Describe Selenium-75 and its properties
• Explain the dosimetry of selenium-75 compare to iridum-192

At the end of the talk, the participant will be able to:

• Review the importance of nomenclature standardisation for safety
• Explain the brachytherapy specific nomenclature standard to be proposed by TG-263U1.
• Discuss future areas for standardisation for brachytherapy

At the end of this talk, the participant will be able to:

• Understand importance of model robustness to change practice
• Perform commissioning and benchmarking of AI models
• Discuss importance of model trans parency

Simultaneous closed session for a maximum of 10 participants

At the end of this activity, the participant will be able to:

• Preparing the patient and planned the implant 
• Perform the implant
• Discuss Dosimetry
• Understand  possible complications and toxicities

At the end of this activity, the participant will be able to:

• Reconstruction of applicator and interstitial catheters on MRI only
• Plan a treatement
• Sum dose to evaluate combined EBRT and brachytherapy plan

At the end of this activity, the participant will be able to:

• Planned the implant according toturn on geometry and localisation
• Discuss dosimetric parameters
• Analyze the feasability of the implat

At the end of this activity, the participant will be able to:

• Understand the role of each member of the team 
• Discuss the benefit of an efficient workflow 
• Identify the strengths of an integrated team

At the end of this activity, the participant will be able to:

• Recognize limitation due to anatomy relationships 
• Discuss dosimetry accommodation

Evaluation for: Hands-on Breast Implant (part 1 & 2)

Sumitomo Pharma: Relugolix

At the end of the presentation, the participant will be able to: 

• List the different situations which can be treated with brachytherapy
• Discuss the use of brachytherapy in this context
• Analyze technique and dosimetry parameters

At the end of this activity, the participant will be able to:

• Understand the ethymology of theses cancers
• Discuss the use of brachytherapy in this context
• Analyze technique and dosimetry parameters

At the end of this presentation, the participant will be able to: 

• List the different indications for intravascular brachytherapy
• Understand the particularities of brachytherapy's workflow 
• Analyze technique and considerations for brachytherapy

At the end of the presentation, the participant will be able to: 

• Understand different consideration according to localization of tumor
• Discuss the use of brachytherapy in this context
• Analyze technique and dosimetry parameters 

At the end of this presentation, the participant will be able to:

• Undesrtand the particularities of brachytherapy for sarcoma
• Discuss dosimetry and applicators
• Analyze the feasibility of the implant

at the end of the presentation, the participant will be able to:

• Understand the place of brachytherapy in the treatement of primary vaginal cancer
• Discuss the use of interstitial brachytherapy in this context
• Analyze different particularities for brachytherapy vaginal cuff recurrences

At the end of this presentations, the participation will be able to:

• Discuss the requirement for access to GYN  brachytherapy
• Understand possible access to image guided brachytherapy
• Analyze the encountered difficulties.

At the end of the presentation, the participant will be able to:

• Understand the particular aspects for access to GYN brachytherapy
• Discuss imaging capacity and improvement in certain toxicity with imaging
• Analyze the response to treatment 

At the end of this presentation the participant will be able to:

• Discuss the global access to GYN brachytherapy
• Understand the obstacle preventing access to GYN brachytherapy
• Analyze possible steps to improve access

At the end of this presentation, the participant will be able to:

• Discuss the cost of HDR brachytherapy in Canada
• Understand the most expensive component of procedure
• Analyze possible steps to improve cost 

At the end of this presentation, the participant will be able to:

• Analyze the relationship between dose and the immune system 
• Outline the different immune pathways triggered by radiation
• Discuss the immunogenicity of radiotherapy

At the end of this presentation, the participant will be able to:

• Analyse the relationship between PSA nadir and prostate cancer recurrence
• Discuss in which recurrence situation brachytherapy can be use
• Understand the results of the literature

At the end of this presentation, the participant will be able to:

• Explain the difference and indications of each technic
• Discuss the long term results of each technic
• Determine the optimal lowest PSA value after salvage brachytherapy

At the end of this presentation, the participant will be able to:

• Discuss the  expected toxicities for reirradiation
• Analyze the toxicity patterns of the different technics
• Outline comorbities which could exacerbate toxicities

At the end of this presentation, the participant will be able to:

• Understand the pathologic findings to determine a gleason score
• Discuss the pathologic changes expected after brachytherapy
• Analyze patterns of cells

At the end of this presentation the participant will be able to:

• Analyse criteria's for salvage prostatectomy
• Discuss the procedure
• Identify challenges and the toxicities of the procedure

At the end of this presentation, the participant will be able to:

• Analyze the duration of ADT with brachytherapy for unfavorable intermediate
• Debate the need for ADT with monotherapy
• Evaluate the indications of ADT and ARAT with monotherapy

At the end of this presentation, the participant will be able to:

• Understand the key radiobiological features of HDR dose fractionation
• Discuss the clinical implications of HDR fractionation on tumor and normal tissues in HDR brachytherapy
• Determine potential strategies to optimize HDR dose fractionation and therapeutic ratio

• Q&A: Interactive Session